Etiqueta: endometrial stem cells
-
Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic
Leo Bockeria, Vladimir Bogin, Olga Bockeria, Tatyana Le, Bagrat Alekyan, Erik J Woods, Amalia A Brown, Thomas E Ichim and Amit N Patel Journal of Translational Medicine 2013, 11:56 doi:10.1186/1479-5876-11-56 Published: 5 March 2013 Heart failure is one of the key causes of morbidity and mortality world-wide. The recent findings that regeneration is possible in…
-
Medistem Inc. Annual Letter to Shareholders
SAN DIEGO, CA–(Marketwire – Jan 4, 2013) – Medistem Inc. ( PINKSHEETS : MEDS ) today issues the following letter to shareholders. Dear Fellow Shareholders, 2012 was marked by significant progress in the development of the Endometrial Regenerative Cell (ERC), our new universal donor «stem cell drug.» Most significantly, we initiated a double blind, placebo…
-
Medistem Advances Type 1 Diabetes Stem Cell Technology Licensed From Yale
SAN DIEGO, CA — (Marketwire) — 09/12/12 — Medistem Inc. (PINKSHEETS: MEDS) announced today completion of the first phase of a joint project with the Shumakov Research Center of Transplantology and Artificial Organs of the Russian Federation and its Russian and CIS licensee ERCell. The collaboration is based on using Endometrial Regenerative Cell (ERC) technology…
-
Endometrial Stem Cells Yeild Postive Clinical Trial Results for Heart Disease
More progress reported on the treatment of heart disease with endometrial stem cells. Neil Riordan, PhD is one of the early pioneers of endometrial stem cell technology. Dr. Riordan is also the Founder and President of the Stem Cell Institute in Panama City, Panama. Positive Two-Month Data From RECOVER-ERC Congestive Heart Failure Trial SAN DIEGO,…
-
Medistem Signs Exclusive Worldwide License With Yale University for Treatment of Type 1 Diabetes Using Stem Cells
Acquisition of Intellectual Property and Data Leads to Expansion of Medistem Therapeutic Pipeline SAN DIEGO, CA, Mar 07, 2012 (MARKETWIRE via COMTEX) — Medistem Inc. (pinksheets:MEDS) and Yale University have signed an exclusive worldwide licensing agreement covering the generation of pancreatic islets from stem cells such as the Endometrial Regenerative Cell (ERC). These pancreatic islets…
-
Medistem Begins Phase II Clinical Trial for Heart Failure
Medistem Inc announced today treatment of 3 heart failure patients in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC) trial. The trial is aimed at assessing safety and efficacy of the company’s Endometrial Regenerative Cell (ERC) stem cell product in 60 heart failure patients who have no available…
-
Differences between Stem Cells from the Placenta and Bone Marrow
Fazekasova et al. Mesenchymal stem cells were historically isolated from the bone marrow as an adherent stem cell population capable of “orthodox” differentiation, meaning that they have ability to become bone, cartilage, and fat. Further research revealed that these cells are also capable of “non-orthodox” differentiation, that is, becoming neurons, hepatocytes, insulin producing cells, and…
-
Protein Found on Endometrial Regenerative Cells Inhibits Immune Attack
Medistem Inc. (PINKSHEETS: MEDS) announced today publication of a peer reviewed paper identifying a molecule found on the company’s lead product, the universal donor Endometrial Regenerative Cell (ERC), as a key component of cellular escape from immune attack. The study, entitled “Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated…